
EquitySector - HealthcareVery High Risk
Regular
NAV (23-Oct-25)
Returns (Since Inception)
Fund Size
₹464 Cr
Expense Ratio
2.40%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+3.97%
+1.30% (Cat Avg.)
Since Inception
+18.89%
— (Cat Avg.)
| Equity | ₹453.35 Cr | 97.68% |
| Others | ₹10.79 Cr | 2.32% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹60.58 Cr | 13.05% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹34 Cr | 7.33% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹27.53 Cr | 5.93% |
| Cipla Ltd | Equity | ₹25.56 Cr | 5.51% |
| Divi's Laboratories Ltd | Equity | ₹22.76 Cr | 4.90% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹19.63 Cr | 4.23% |
| Fortis Healthcare Ltd | Equity | ₹19.4 Cr | 4.18% |
| Lupin Ltd | Equity | ₹18.16 Cr | 3.91% |
| Jubilant Pharmova Ltd | Equity | ₹15.11 Cr | 3.26% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹14 Cr | 3.02% |
| Gland Pharma Ltd | Equity | ₹13.94 Cr | 3.00% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹13.48 Cr | 2.90% |
| Anthem Biosciences Ltd | Equity | ₹12.94 Cr | 2.79% |
| Dr Reddy's Laboratories Ltd | Equity | ₹12.24 Cr | 2.64% |
| Mankind Pharma Ltd | Equity | ₹12.18 Cr | 2.62% |
| Alkem Laboratories Ltd | Equity | ₹11.94 Cr | 2.57% |
| Triparty Repo | Cash - Repurchase Agreement | ₹11.9 Cr | 2.56% |
| Acutaas Chemicals Ltd | Equity | ₹11.86 Cr | 2.56% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹11.13 Cr | 2.40% |
| Aurobindo Pharma Ltd | Equity | ₹10.95 Cr | 2.36% |
| Ajanta Pharma Ltd | Equity | ₹10.83 Cr | 2.33% |
| Sai Life Sciences Ltd | Equity | ₹10.33 Cr | 2.23% |
| Laxmi Dental Ltd | Equity | ₹9.76 Cr | 2.10% |
| Marksans Pharma Ltd | Equity | ₹8.25 Cr | 1.78% |
| Innova Captab Ltd | Equity | ₹8.1 Cr | 1.75% |
| Zydus Lifesciences Ltd | Equity | ₹7.86 Cr | 1.69% |
| Krsnaa Diagnostics Ltd | Equity | ₹7.57 Cr | 1.63% |
| Orchid Pharma Ltd | Equity | ₹7.02 Cr | 1.51% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹6.67 Cr | 1.44% |
| Rainbow Childrens Medicare Ltd | Equity | ₹6.32 Cr | 1.36% |
| Hikal Ltd | Equity | ₹3.27 Cr | 0.70% |
| Net Current Assets/(Liabilities) | Cash | ₹-1.11 Cr | 0.24% |
Large Cap Stocks
45.88%
Mid Cap Stocks
13.84%
Small Cap Stocks
35.16%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹441.49 Cr | 95.12% |
| Basic Materials | ₹11.86 Cr | 2.56% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better

Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.40% | Exit Load No Charges | Fund Size ₹464 Cr | Age 1 year 10 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹5,58,073 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (23-Oct-25)
Returns (Since Inception)
Fund Size
₹464 Cr
Expense Ratio
2.40%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+3.97%
+1.30% (Cat Avg.)
Since Inception
+18.89%
— (Cat Avg.)
| Equity | ₹453.35 Cr | 97.68% |
| Others | ₹10.79 Cr | 2.32% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹60.58 Cr | 13.05% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹34 Cr | 7.33% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹27.53 Cr | 5.93% |
| Cipla Ltd | Equity | ₹25.56 Cr | 5.51% |
| Divi's Laboratories Ltd | Equity | ₹22.76 Cr | 4.90% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹19.63 Cr | 4.23% |
| Fortis Healthcare Ltd | Equity | ₹19.4 Cr | 4.18% |
| Lupin Ltd | Equity | ₹18.16 Cr | 3.91% |
| Jubilant Pharmova Ltd | Equity | ₹15.11 Cr | 3.26% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹14 Cr | 3.02% |
| Gland Pharma Ltd | Equity | ₹13.94 Cr | 3.00% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹13.48 Cr | 2.90% |
| Anthem Biosciences Ltd | Equity | ₹12.94 Cr | 2.79% |
| Dr Reddy's Laboratories Ltd | Equity | ₹12.24 Cr | 2.64% |
| Mankind Pharma Ltd | Equity | ₹12.18 Cr | 2.62% |
| Alkem Laboratories Ltd | Equity | ₹11.94 Cr | 2.57% |
| Triparty Repo | Cash - Repurchase Agreement | ₹11.9 Cr | 2.56% |
| Acutaas Chemicals Ltd | Equity | ₹11.86 Cr | 2.56% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹11.13 Cr | 2.40% |
| Aurobindo Pharma Ltd | Equity | ₹10.95 Cr | 2.36% |
| Ajanta Pharma Ltd | Equity | ₹10.83 Cr | 2.33% |
| Sai Life Sciences Ltd | Equity | ₹10.33 Cr | 2.23% |
| Laxmi Dental Ltd | Equity | ₹9.76 Cr | 2.10% |
| Marksans Pharma Ltd | Equity | ₹8.25 Cr | 1.78% |
| Innova Captab Ltd | Equity | ₹8.1 Cr | 1.75% |
| Zydus Lifesciences Ltd | Equity | ₹7.86 Cr | 1.69% |
| Krsnaa Diagnostics Ltd | Equity | ₹7.57 Cr | 1.63% |
| Orchid Pharma Ltd | Equity | ₹7.02 Cr | 1.51% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹6.67 Cr | 1.44% |
| Rainbow Childrens Medicare Ltd | Equity | ₹6.32 Cr | 1.36% |
| Hikal Ltd | Equity | ₹3.27 Cr | 0.70% |
| Net Current Assets/(Liabilities) | Cash | ₹-1.11 Cr | 0.24% |
Large Cap Stocks
45.88%
Mid Cap Stocks
13.84%
Small Cap Stocks
35.16%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹441.49 Cr | 95.12% |
| Basic Materials | ₹11.86 Cr | 2.56% |
Standard Deviation
This fund
--
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better

Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.40% | Exit Load No Charges | Fund Size ₹464 Cr | Age 1 year 10 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹5,58,073 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments